

Amended Claims for International Application No. PCT/EP03/06094**We Claim:**

1. A multivalent meningococcal bleb composition comprising a bleb preparation deficient in PorA in that it has less than 80% of the amount of PorA as compared to the same quantity of blebs made from strain H44/76 and a bleb preparation that is not deficient in PorA compared to blebs made from strain H44/76.
2. The multivalent meningococcal bleb composition of claim 1, wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype that is prevalent in a country of use.
3. The multivalent meningococcal bleb composition of claim 1 or 2, wherein the bleb preparation deficient in PorA has less than 22% PorA of total bleb protein, or lacks PorA.
4. The multivalent meningococcal bleb composition of claims 1-3, wherein the bleb preparation not deficient in PorA has more than 28% PorA of total bleb protein.
5. The multivalent meningococcal bleb composition of claims 1-4, wherein the bleb preparation deficient in PorA is derived from the meningococcal CU-385 strain.
6. A vaccine for the treatment of neisserial, preferably meningococcal, disease comprising the multivalent meningococcal bleb composition of claims 1-5, and a pharmaceutically acceptable excipient.
7. The vaccine of claim 6 additionally comprising one or more plain or conjugated meningococcal capsular polysaccharides selected from the following list of serotypes: A, C, Y and W.
8. The vaccine of claim 6 or 7 suitable for use in New Zealand or Europe wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.4.

9. The vaccine of claim 6 or 7 suitable for use in USA where the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.7,16.

10. The vaccine of claim 6 or 7 suitable for use in Norway wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.16.

11. A method of manufacturing the multivalent meningococcal bleb composition of claims 1-5 or the vaccine of claims 6-10 comprising the step of combining the bleb preparation that is not deficient in PorA with the bleb preparation that is deficient in PorA.

12. A method of preventing or treating neisserial, preferably meningococcal, disease comprising the step of administering an immunologically effective amount of the vaccine of claims 6-10 to a host in need thereof.

13. The use of an immunologically effective amount of the vaccine of claims 6-10 in the manufacture of a medicament for the prevention or treatment of neisserial, preferably meningococcal, disease.